🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At #SITC2023 in San Diego, CA, MiNK to present updated clinical data and insights into the novel mechanisms of our lead program, agenT-797, in solid tumor cancers. Learn more: investor.minktherapeutics.com/news-releases/…

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023 - Bloomberg #SITC #cancer #immunotherapy bloomberg.com/press-releases…

Today MiNK presented new data demonstrating the clinical activity and long-term persistence of our allogeneic iNKT cells, agenT-797, in heavily pre-treated solid tumors at #SITC2023. Learn more: bit.ly/45T3Xvq #iNKT #CellTherapy #CancerResearch

MiNK announced its third quarter 2023 financial results and provided a corporate update, highlighting advancements across its iNKT cell therapy platform. Read more about these results: bit.ly/3QRNNOy #iNKT #CellTherapy

MiNK and ImmunoScape collaborate to develop next-generation TCRs for solid tumors. The partnership aims to accelerate the development of TCR-based therapies against novel targets in T cells, #iNKT cells, and other modalities. Learn more: bit.ly/3v40HQZ

New publication from Oncogene Journal spotlights a compelling case study of a durable response to our investigational #iNKT cell therapy, agenT-797 in PD-1 refractory gastric cancer. Read more about the potential of iNKT cells to combat resistance to ICIs: bit.ly/3unw0WW

Today @naturecomms published results from our trial of allogeneic iNKT cells in ARDS, highlighting the unique attributes of iNKTs and their potential in mitigating respiratory illnesses. We thank all the patients who participated in this study. Learn more: bit.ly/494j6MC

We are proud to partner with Yelena Y. Janjigian MD on a phase 2 study in 2L gastroesophageal cancers. The first patient has been dosed, and the trial will investigate our allo-iNKT cell therapy, agenT-797, in combination with Agenus's BOT/BAL, and chemo. bit.ly/42DvK2S

Today MiNK Chief Scientific Officer, Marc van Dijk, joins the CAR-TCR Summit Europe, where he will discuss our clinical experience with allogeneic iNKTs and the exciting future for this novel cell therapy approach. Learn more: cartcr-europe.com #iNKT #CellTherapy

Stay tuned for MiNK’s upcoming presentation at #AACR24. On April 8, MiNK will present preclinical data on MiNK-215, our IL-15 armored FAP-targeting CAR-iNKT cell therapy, demonstrating its unique potential against liver metastases in MSS CRC. Learn more: bit.ly/4c5Y8yQ

Today we recognize and thank all the women who inspire, lead, and break barriers. MiNK is proud to #InspireInclusion with our dedicated team of female leaders who help pioneer our commitment to delivering #iNKT cell therapies for patients. #InternationalWomensDay #IWD2024

Today we announced fourth quarter and year-end of 2023 results. Our year was marked by progress across our clinical programs, manufacturing, and research team, which continue to solidify our leadership in the field of #iNKT cell therapy. Read more: bit.ly/43uBFHR

#ICYMI - check out our presentation from #AACR2024 yesterday: minktherapeutics.com/publications/ Thank you to everyone who stopped by our poster session to hear new preclinical data on MiNK-215’s activity against colorectal cancer liver metastases. #CellTherapy #CancerResearch #INKT

Today we’ve announced a $5.8M in private placement financing to accelerate MiNK-215's clinical development and the appointment of a Board Observer. Learn more: bit.ly/3UHIcv7

This quarter we made significant strides across our iNKT cell programs, including generating clinical data from our agenT-797 program, strengthening our financial position, and advancing our innovative next-generation therapies. Read more in our Q1 report: bit.ly/3yrUjEN

Yesterday Dr. Terese Hammond presented data at the American Thoracic Society #ATS2024 Annual Meeting in San Diego, CA, showcasing the clinical activity of MiNK’s allogeneic iNKT cells in respiratory distress. Learn more: bit.ly/4bPoRie

Bot/Bal #immunotherapy in #coloncancer #NEST 1/2 Agenus with very promising data in early MSI-s/MSI-H #coloncancer ! ESMO - Eur. Oncology #ESMOGI24 #ESMOAmbassadors OncoAlert #CancerResearch #cancer

We are excited to announce a new collaboration with Autonomous Therapeutics. By combining our iNKT cell platform with their encrypted RNA technology, we aim to develop innovative and potentially transformative therapies for metastatic cancers. Learn more: bit.ly/4eQGXSy

MiNK is live in Los Angeles for #AACRIO25. Tune in later today to hear new translational data from the ongoing Ph2 study evaluating allo-iNKTs (agenT-797) in combination with Agenus's BOT/BAL & chemotherapy in refractory #GastricCancer. Learn more: bit.ly/3XhoXKS

Yesterday at #AACRIO25, we presented new translational insights highlighting the powerful synergy between MiNK’s allo-iNKT cells, checkpoint inhibitors, and chemotherapy in #GastricCancer. Read more about the data: bit.ly/3XhoXKS